FIELD: medicine.
SUBSTANCE: invention refers to immunology, and can be used for administering oligohitozane derivative as adjuvant for vaccines. Oligohitozane derivative consists of links glucosamine 91-98 % and (N-acyl)glucosamine 2-9 % with molecular weight from 5 to 15 kDa.
EFFECT: using this invention makes it possible to apply oligohitozane derivative as new adjuvants, increasing immunogenicity of vaccines and having low haemostatic activity.
3 cl, 5 ex, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD TO INCREASE IMMUNOGENICITY OF INACTIVATED FLUE VACCINE | 2007 |
|
RU2323742C1 |
IMMUNOADJUVANT COMPOSITION FOR VACCINES FOR INFECTIOUS AGENTS OF VIRAL AND BACTERIAL NATURE | 2018 |
|
RU2697527C1 |
METHOD FOR IMPROVING IMMUNOGENICITY OF COLD-ADAPTED LIVE INFLUENZA VACCINE | 2010 |
|
RU2465006C2 |
ADJUVANT FOR ANTI-VIRAL VACCINES | 2017 |
|
RU2676266C2 |
RECOMBINANT PLASMID DNA pPA-OPRF-ETA CODING SYNTHESIS OF RECOMBINANT PROTEIN OPRF-ETA Pseudomonas aeruginosa, STRAIN Escherichia coli PA-OPRF-ETA PRODUCING RECOMBINANT PROTEIN OPRF-ETA Pseudomonas aeruginosa AND METHOD FOR PREPARING RECOMBINANT PROTEIN OPRF-ETA Pseudomonas aeruginosa | 2012 |
|
RU2529359C2 |
STRAINS OF Streptococcus pneumoniae (VERSIONS) AND METHOD OF PRODUCING PROTECTIVE PROTEIN FRACTION, POSSESSING INTRASPECIFIC IMMUNOGENIC ACTIVITY | 2015 |
|
RU2601158C1 |
METHOD FOR ENCAPSULATING ALLERGENS INTO CHITOSAN PARTICLES TO REDUCE RECOGNITION OF ALLERGENS BY IgE ANTIBODIES DURING ALLERGEN-SPECIFIC SUBCUTANEOUS AND TRANSEPIDERMAL IMMUNOTHERAPY | 2020 |
|
RU2760672C1 |
RECOMBINANT PLASMID pPA-OPRFI DNA CODING HYBRID RECOMBINANT F-I PROTEIN OF Pseudomonas aeruginosa OUTER MEMBRANE, STRAIN Escherichia coli PA-OPRFI PRODUCING HYBRID RECOMBINANT F-I PROTEIN OF Pseudomonas aeruginosa OUTER MEMBRANE AND METHOD FOR PRODUCING HYBRID RECOMBINANT F-I PROTEIN OF Pseudomonas aeruginosa OUTER MEMBRANE | 2011 |
|
RU2537006C2 |
UNIVERSAL AVIAN INFLUENZA VIRUS VACCINE | 2007 |
|
RU2358981C2 |
METHOD FOR OBTAINING ATTENUATED STRAINS OF INFLUENZA A VIRUS - CANDIDATES FOR LIVE INFLUENZA VACCINES | 2017 |
|
RU2670514C1 |
Authors
Dates
2016-07-10—Published
2015-04-29—Filed